Xiaofang Pharmaceuticals has surged by nearly 213%, with a 30% increase compared to the opening price, triggering a trading halt. The company's products cover various subsectors such as digestive, skincare, and ophthalmology, with a higher proportion of revenue coming from the digestive category. The main products include laxatives and povidone-iodine solution.
N小方大涨近213% 触发临停
N Xiaofang soared nearly 213% and triggered a temporary halt.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.